| AXIS Capital Declares Quarterly Dividends |
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited ("AXIS Capital" or the “Company”) (NYSE: AXS) today announced that its Board of Directors has declared a quarterly dividend of $0.44 per common share payable on July 17, 2025 to shareholders of record at the close of business on June 30, 2025. In addition, the Board declared a dividend of $34.375 per Series E 5.50% preferred share (equivalent to $0.34375 per depositary share) payable on July 17, 2025 to shareholders of record at. |
businesswire.com |
2025-05-15 20:15:00 |
Czytaj oryginał (ang.) |
| Here's Why Axis Capital (AXS) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-15 14:56:23 |
Czytaj oryginał (ang.) |
| 4 Stocks With Impressive Interest Coverage Ratio to Buy Now |
STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships. |
zacks.com |
2025-05-14 16:26:16 |
Czytaj oryginał (ang.) |
| AXIS Capital Stock Near 52-Week High: Is This Your Buy Signal? |
AXS gains from a well-performing specialty insurance, reinsurance, as well as the accident and health portfolio. |
zacks.com |
2025-05-13 13:55:24 |
Czytaj oryginał (ang.) |
| Axis Capital Holdings Limited (AXS) Soars to 52-Week High, Time to Cash Out? |
Axis Capital (AXS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2025-05-12 14:15:59 |
Czytaj oryginał (ang.) |
| Tap These 5 Bargain Stocks With Impressive EV-to-EBITDA Ratio |
We have screened bargain stocks NOMD, ASLE, BJRI, AXS and AVA based on the EV-to-EBITDA ratio, which gives the true picture of valuation and earnings potential. |
zacks.com |
2025-05-07 11:10:38 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns |
Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competitive depression market, but its success is heavily reliant on aggressive marketing and significant spending. Upcoming launches and regulatory submissions for Symbravo, AXS-14, AXS-05, and AXS-12 face stiff competition and potential regulatory hurdles. |
seekingalpha.com |
2025-05-06 16:48:47 |
Czytaj oryginał (ang.) |
| AXS or CB: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Axis Capital (AXS) and Chubb (CB). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-05-02 16:41:09 |
Czytaj oryginał (ang.) |
| Here's Why Axis Capital (AXS) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-02 14:46:16 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Axis Capital Holdings (AXS) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-05-02 14:45:50 |
Czytaj oryginał (ang.) |
| AXIS Capital Holdings Limited (AXS) Q1 2025 Earnings Call Transcript |
AXIS Capital Holdings Limited (NYSE:AXS ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Cliff Gallant - Head, Investor Relations Vince Tizzio - President & Chief Executive Officer Pete Vogt - Chief Financial Officer Conference Call Participants Andrew Kligerman - TD Securities Christian Getzoff - Wells Fargo Meyer Shields - KBW Andrew Andersen - Jefferies Charlie Lederer - BMO Josh Shanker - Bank of America Operator Good day, and welcome to the First Quarter 2025 AXIS Capital Earnings Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-05-01 19:05:42 |
Czytaj oryginał (ang.) |
| AXIS Capital Q1 Earnings Beat Estimates on Higher Investment Income |
AXS' first-quarter results reflect solid underwriting income, improved investment income, and higher premiums across the segments, offset by escalating expenses. |
zacks.com |
2025-05-01 15:25:40 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Axis Capital (AXS) Q1 Earnings |
While the top- and bottom-line numbers for Axis Capital (AXS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-01 02:00:29 |
Czytaj oryginał (ang.) |
| Axis Capital (AXS) Q1 Earnings Beat Estimates |
Axis Capital (AXS) came out with quarterly earnings of $3.17 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.57 per share a year ago. |
zacks.com |
2025-04-30 23:20:31 |
Czytaj oryginał (ang.) |
| AXIS Capital Reports First Quarter Net Income Available to Common Shareholders of $187 Million, or $2.26 Per Diluted Common Share and Operating Income of $261 Million, or $3.17 Per Diluted Common Share |
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited ("AXIS Capital" or "AXIS" or "the Company") (NYSE: AXS) today announced financial results for the first quarter ended March 31, 2025. Commenting on the first quarter 2025 financial results, Vince Tizzio, President and CEO of AXIS Capital said: "AXIS delivered another strong quarter of consistent, profitable performance as we continued to lean into our specialty underwriting value proposition, while helping our customers navigate. |
businesswire.com |
2025-04-30 20:15:00 |
Czytaj oryginał (ang.) |
| AXIS Completes Previously Announced Transaction With Enstar |
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or the “Company”) (NYSE: AXS) and Enstar Group Limited (“Enstar”) (Nasdaq: ESGR) announced today that they have completed a loss portfolio transfer (“LPT”) transaction, covering reinsurance segment reserves predominantly attributable to casualty portfolios related to 2021 and prior underwriting years. The LPT reinsurance agreement covers reinsurance segment reserves totalling $3.1 billion at September 30. |
businesswire.com |
2025-04-24 20:05:00 |
Czytaj oryginał (ang.) |
| Axis Capital (AXS) Reports Next Week: Wall Street Expects Earnings Growth |
Axis Capital (AXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-23 15:07:49 |
Czytaj oryginał (ang.) |
| AXS vs. CB: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Axis Capital (AXS) and Chubb (CB). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-04-16 16:46:24 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Axis Capital Holdings (AXS) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-04-16 14:46:25 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm |
NEW YORK , April 8, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Axsome caused the company to misrepresent or fail to disclose (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times. |
prnewswire.com |
2025-04-08 18:03:00 |
Czytaj oryginał (ang.) |
| Edison Issues Report on Accsys Technologies (AXS) |
London, United Kingdom--(Newsfile Corp. - February 25, 2025) - Edison issues report on Accsys Technologies (AIM: AXS). At its investor strategy day, Accsys set financial targets for the coming years, with a combined volume and revenue CAGR of 14% for FY25-30e for the plant in the Netherlands and the Accoya USA plant (60%/40% joint venture (JV)). |
newsfilecorp.com |
2025-02-25 07:32:00 |
Czytaj oryginał (ang.) |
| AXS Stock Trading at Discount to Industry at 1.38X: Time to Hold? |
AXIS Capital stock is poised to gain from a well-performing specialty insurance, reinsurance as well as the accident and health portfolio. |
zacks.com |
2025-02-20 12:55:37 |
Czytaj oryginał (ang.) |
| Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade |
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth. |
seekingalpha.com |
2025-02-11 19:20:43 |
Czytaj oryginał (ang.) |
| AXIS Capital Holdings Limited (AXS) Q4 2024 Earnings Call Transcript |
AXIS Capital Holdings Limited (NYSE:AXS ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Cliff Gallant - Head, Investor Relations Vince Tizzio - President and Chief Executive Officer Pete Vogt - Chief Financial Officer Conference Call Participants Andrew Kligerman - TD Securities Yaron Kinar - Jefferies Brian Meredith - UBS Josh Shanker - Bank of America Charlie Lederer - BMO Operator Good morning, and welcome to the AXIS Capital Fourth Quarter 2024 Conference Call. All participants will be in a listen-only mode. |
seekingalpha.com |
2025-01-30 19:43:06 |
Czytaj oryginał (ang.) |
| AXIS Capital Q4 Earnings Top Estimates on Solid Underwriting |
AXS' fourth-quarter results reflect improved net investment income and higher premiums, offset by higher expenses. |
zacks.com |
2025-01-30 14:41:29 |
Czytaj oryginał (ang.) |
| Axis Capital (AXS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Axis Capital (AXS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-01-29 23:01:28 |
Czytaj oryginał (ang.) |
| Axis Capital (AXS) Q4 Earnings Beat Estimates |
Axis Capital (AXS) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.68 per share. This compares to earnings of $2.94 per share a year ago. |
zacks.com |
2025-01-29 20:50:20 |
Czytaj oryginał (ang.) |
| AXIS Capital Reports Fourth Quarter Net Income Available to Common Shareholders of $286 Million, or $3.38 Per Diluted Common Share and Operating Income of $252 Million, or $2.97 Per Diluted Common Share |
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited ("AXIS Capital" or "AXIS" or "the Company") (NYSE: AXS) today announced financial results for the fourth quarter ended December 31, 2024. Commenting on the 2024 financial results, Vince Tizzio, President and CEO of AXIS Capital, said: "2024 was an excellent year for AXIS. We delivered on the financial and operational guideposts that we shared at our Investor Day this past May, highlighted by an operating return-on-equity of 18.6%. |
businesswire.com |
2025-01-29 18:15:00 |
Czytaj oryginał (ang.) |
| Why Axis Capital (AXS) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-01-29 12:46:38 |
Czytaj oryginał (ang.) |
| Here's Why Axis Capital (AXS) is a Strong Momentum Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-01-28 12:50:23 |
Czytaj oryginał (ang.) |
| Earnings Preview: Axis Capital (AXS) Q4 Earnings Expected to Decline |
Axis Capital (AXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-22 13:06:56 |
Czytaj oryginał (ang.) |
| AXIS Capital to Release Fourth Quarter Financial Results on January 29, 2025 |
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results for the fourth quarter ended December 31, 2024 on Wednesday, January 29, 2025 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Peter Vogt, Chief Financial Officer, will host an investor teleconference, including a question and answer period, on Thursday, January 30, 2025 at 8. |
businesswire.com |
2025-01-06 18:15:00 |
Czytaj oryginał (ang.) |
| Sara Farrup Becomes AXIS Head of Global Markets |
PEMBROKE, Bermuda--(BUSINESS WIRE)--AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or the “Company”) (NYSE: AXS) today announced Sara Farrup (nee Mitchell) has assumed the role of Head of Global Markets as part of a planned leadership transition, first announced in September 2024. Ms. Farrup, who reports to AXIS President and CEO Vince Tizzio and is part of the Company's Executive Committee, succeeds longtime Head of Global Markets Mark Gregory, who will continue to serve as a strategi. |
businesswire.com |
2025-01-06 10:45:00 |
Czytaj oryginał (ang.) |
| AXS Rallies 58.5% in a Year: A Signal for Investors to Hold Tight? |
AXIS Capital stock rallies on the back of well-performing specialty insurance, reinsurance as well as the accident and health portfolio. |
zacks.com |
2025-01-03 13:10:31 |
Czytaj oryginał (ang.) |
| Will Axis Capital (AXS) Beat Estimates Again in Its Next Earnings Report? |
Axis Capital (AXS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-01-02 15:10:36 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results |
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AXS-07 for migraine (PDUFA: January 31, 2025), AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Despite mixed Phase 3 results for AXS-05 in Alzheimer's agitation, the overall data is favorable, supporting a bullish outlook. |
seekingalpha.com |
2024-12-31 11:15:44 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation |
ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) |
globenewswire.com |
2024-12-30 09:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Axis Capital (AXS) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-26 12:46:19 |
Czytaj oryginał (ang.) |
| 3 P&C Insurance Stocks That Have Gained More Than 50% in 2024 |
Despite higher catastrophe losses, MCY, AXS and PLMR not only outperforms the industry but also crushes the Zacks S&P 500 composite and the Finance sector. |
zacks.com |
2024-12-24 13:21:17 |
Czytaj oryginał (ang.) |
| AXIS Capital: A Niche Leader Priced For NOPAT Fall |
AXIS Capital is a global leader in specialty insurance and reinsurance, with a 30.2% annual NOPAT growth and a 15.3% ROIC in TTM. The company's diversified portfolio, disciplined risk management, and innovation focus position it to continue delivering value despite market challenges. AXIS's market valuation implies a 31% decline in future NOPAT, presenting a compelling investment opportunity given its strong historical performance. |
seekingalpha.com |
2024-12-22 23:00:22 |
Czytaj oryginał (ang.) |
| AXIS Advances Transition to Specialty Underwriter, Announces Loss Portfolio Transfer Reinsurance Agreement With Enstar on Reinsurance Segment Reserves |
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or “the Company”) (NYSE: AXS) and Enstar Group Limited (“Enstar”) (Nasdaq: ESGR) today announced that they have entered into a loss portfolio transfer (“LPT”) reinsurance agreement covering a portfolio of reinsurance segment business. The closing of the transaction is subject to regulatory approvals and other customary conditions, and is expected to occur during the first half of 2025. Under the LPT rein. |
businesswire.com |
2024-12-16 18:05:00 |
Czytaj oryginał (ang.) |
| Why Axis Capital (AXS) is a Top Momentum Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-12 12:55:26 |
Czytaj oryginał (ang.) |
| AXIS President and CEO Vince Tizzio and CFO Pete Vogt to Speak at the 2024 UBS Global Specialty Insurance/Reinsurance Virtual Conference |
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited ("AXIS Capital" or the “Company”) (NYSE: AXS) today announced that its President and CEO Vince Tizzio and CFO Pete Vogt will participate in a fireside chat with UBS analyst Brian Meredith at the 2024 UBS Global Specialty Insurance/Reinsurance Virtual Conference. The fireside chat will take place on December 17, 2024 at 9:15 am eastern. There will be a live webcast during the presentation, and an archived replay will be available. |
businesswire.com |
2024-12-11 18:15:00 |
Czytaj oryginał (ang.) |
| Why Axis Capital (AXS) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-10 12:41:31 |
Czytaj oryginał (ang.) |
| Is Axis Capital Holdings (AXS) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-09 12:46:35 |
Czytaj oryginał (ang.) |
| Is Axis Capital Holdings (AXS) Stock Outpacing Its Finance Peers This Year? |
Here is how Axis Capital (AXS) and Mr Cooper (COOP) have performed compared to their sector so far this year. |
zacks.com |
2024-12-09 12:41:08 |
Czytaj oryginał (ang.) |
| AXS or TKOMY: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Axis Capital (AXS) and Tokio Marine Holdings Inc. (TKOMY). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2024-12-09 08:48:18 |
Czytaj oryginał (ang.) |
| AXIS Capital Declares Quarterly Dividends |
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited ("AXIS Capital" or the “Company”) (NYSE: AXS) today announced that its Board of Directors has declared a quarterly dividend of $0.44 per common share payable on January 15, 2025 to shareholders of record at the close of business on December 31, 2024. In addition, the Board declared a dividend of $34.375 per Series E 5.50% preferred share (equivalent to $0.34375 per depositary share) payable on January 15, 2025 to shareholders of. |
businesswire.com |
2024-12-05 18:15:00 |
Czytaj oryginał (ang.) |
| 5 Low Price-to-Book Value Stocks to Buy in December |
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, SEM, AXS, ZIM and PFE are some such stocks. |
zacks.com |
2024-12-02 10:45:52 |
Czytaj oryginał (ang.) |
| 4 Best Value Stocks to Invest in This December for Strong Returns |
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, AXS, PFE & GM boast a low P/CF ratio. |
zacks.com |
2024-11-29 18:01:13 |
Czytaj oryginał (ang.) |
| Why Is Axis Capital (AXS) Up 19.9% Since Last Earnings Report? |
Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-29 14:37:58 |
Czytaj oryginał (ang.) |
| Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data |
Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial, with current treatments having issues like tolerability and efficacy, which AXS-12 aims to address effectively. Financially, Axsome has a market cap of $4.83bn, strong revenue growth, but a net loss, indicating a cash runway of four to five quarters. |
seekingalpha.com |
2024-11-29 12:32:32 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says |
On Tuesday, Axsome Therapeutics Inc AXSM said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial. |
benzinga.com |
2024-11-27 15:23:19 |
Czytaj oryginał (ang.) |